{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:46Z","timestamp":1787026606882,"version":"build-2736575974"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Psoriasis and psoriatic arthritis, together known as psoriatic disease, is highly prevalent chronic relapsing inflammatory disease affecting skin, joints or both and is associated with several comorbidities such as cardiovascular, metabolic, psychiatric, renal disease etc. The etiopathogenesis of psoriasis is complex and mainly driven by aberrant immune response owing to the genetic susceptibility and various environmental factors such as trauma, infections and drugs. Recent advances in understanding molecular and cellular pathways have identified tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin-17 (IL-17), IL-23, IL-22 as major contributors in psoriasis pathogenesis. Advances in the knowledge of pathophysiology, the interaction of autoinflammation and clinical phenotypes have led to the development of highly effective targeted therapeutic agents which include TNF-\u03b1, IL-17, IL-23, IL-1 \u03b1\/\u03b2 or IL-36 inhibitors or receptor blockers, small molecule drugs like phosphodiesterase-4 inhibitors (apremilast), Janus kinase (JAK) inhibitors, retinoic acid receptor-related orphan receptor \u03b3t (ROR\u03b3t) inhibitors. These novel drugs have promised the potential of improved disease control. In recent years, the transition from biologics to biosimilars especially with TNF-\u03b1 inhibitors had significant impact on decreasing health care cost and increasing therapeutic options to the patients. However, selection of right treatment for an individual patient still remains challenging. Moreover, interplay between different epigenetic mechanisms such as the DNA methylation, chromatin modifications and noncoding RNA regulation has recently been started to be deciphered. Enzymes inhibitors involved in epigenetic pathways such as DNA methyltransferases and histone deacetylases demonstrated to restore normal epigenetic patterns in clinical settings and have provided the potential as novel therapeutic targets for psoriasis. In this review, we will discuss novel biologic agents and newer therapeutic approaches in treatment of psoriatic disease.<\/jats:p>","DOI":"10.3389\/fmed.2022.712313","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T23:37:25Z","timestamp":1645400245000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Novel Therapeutic Target(s) for Psoriatic Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Vishal","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"a011205","DOI":"10.1101\/cshperspect.a011205","article-title":"The Jak\/STAT pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.12049","article-title":"STAT1 expression and activation is increased in lesional psoriatic skin","volume":"168","author":"Hald","year":"2013","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms19010171","article-title":"Psoriasis: a STAT3-Centric view","volume":"19","author":"Calautti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","article-title":"Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model","volume":"11","author":"Sano","year":"2005","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab vs. placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","article-title":"Topical Janus kinase inhibitors: a review of applications in dermatology","volume":"79","author":"Hosking","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral Janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdermsci.2009.01.003","article-title":"Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis","volume":"54","author":"Yawalkar","year":"2009","journal-title":"J Dermatol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/cells9092044","article-title":"Decoding IL-23 signaling cascade for new therapeutic opportunities","volume":"9","author":"Pastor-Fern\u00e1ndez","year":"2020","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0220868","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer","year":"2019","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball","year":"2012","journal-title":"Br J Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/1203475420932514","article-title":"Long-term single center experience in treating plaque psoriasis with guselkumab","volume":"24","author":"Maliyar","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"B33","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jdv.16964","article-title":"Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial","volume":"35","author":"Warren","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs. treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms20133318","article-title":"The Significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36\u03b3 (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D'Erme","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/exd.13841","article-title":"IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis","volume":"28","author":"Su","year":"2019","journal-title":"Exp Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"eaan2514","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36\u03b3 Antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1203475419888862","article-title":"Spesolimab: a novel treatment for pustular psoriasis","volume":"24","author":"Ratnarajah","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"B46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/1744666X.2021.1886081","article-title":"The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives","volume":"17","author":"Iznardo","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A critical role of the IL-1\u03b2-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jid.2020.07.012","article-title":"Enhanced inflammasome activity in patients with psoriasis promotes systemic inflammation","volume":"141","author":"Verma","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bjd.13012","article-title":"Partial clinical response to anakinra in severe palmoplantar pustular psoriasis","volume":"171","author":"Tauber","year":"2014","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the treatment of pustular psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B51","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful response in a case of severe pustular psoriasis after interleukin-1\u03b2 inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fimmu.2018.01210","article-title":"Transcription factor retinoid-related orphan receptor \u03b3t: a promising target for the treatment of psoriasis","volume":"9","author":"Tang","year":"2018","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc) Inhibitors: Hits and Misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J Med Chem"},{"key":"B55","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jdermsci.2019.03.002","article-title":"A novel ROR\u03b3t inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations","volume":"93","author":"Imura","year":"2019","journal-title":"J Dermatol Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ng.694","article-title":"A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1","volume":"42","author":"Strange","year":"2010","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B60","first-page":"37","article-title":"A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis","volume-title":"Experimental Dermatology","author":"Forman","year":"2018"},{"key":"B61","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrd4099","article-title":"Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond","volume":"12","author":"Kunkel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"B62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/sj.jid.5701259","article-title":"Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype","volume":"128","author":"Sch\u00fcppel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation","volume":"337","author":"Piali","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A(3) adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med Res Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2310970","DOI":"10.1155\/2018\/2310970","article-title":"Inhibition of IL-17 and IL-23 in human keratinocytes by the A(3) adenosine receptor agonist piclidenoson","volume":"2018","author":"Cohen","year":"2018","journal-title":"J Immunol Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1038\/cddis.2012.69","article-title":"Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis","volume":"3","author":"Madonna","year":"2012","journal-title":"Cell Death Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/jid.2012.123","article-title":"Interleukin-1\u03b2 interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis","volume":"132","author":"Buerger","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/exd.12779","article-title":"8-methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of mTOR pathway in psoriatic skin of K5.hTGF\u03b21 transgenic mice","volume":"24","author":"Shirsath","year":"2015","journal-title":"Exp Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3389\/fimmu.2018.02786","article-title":"Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target","volume":"9","author":"Buerger","year":"2018","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.immuni.2017.04.028","article-title":"MenTORing immunity: mTOR signaling in the development and function of tissue-resident immune cells","volume":"46","author":"Jones","year":"2017","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cellimm.2009.03.020","article-title":"The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease","volume":"258","author":"Ochaion","year":"2009","journal-title":"Cell Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br J Dermatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/dth.12176","article-title":"Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis","volume":"28","author":"Wei","year":"2015","journal-title":"Dermatol Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2133.2005.06438.x","article-title":"Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial","volume":"152","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/ced.14269","article-title":"Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review","volume":"45","author":"Paganelli","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2133.2012.10900.x","article-title":"Effect of biologic therapies targeting tumour necrosis factor-\u03b1 on cutaneous mesenchymal stem cells in psoriasis","volume":"167","author":"Campanati","year":"2012","journal-title":"Br J Dermatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.amjmed.2015.11.001","article-title":"Treatment of psoriasis with mesenchymal stem cells","volume":"129","author":"Chen","year":"2016","journal-title":"Am J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3727\/096368916X691998","article-title":"Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report","volume":"25","author":"De Jesus","year":"2016","journal-title":"Cell Transplant"},{"key":"B82","doi-asserted-by":"publisher","first-page":"8309103","DOI":"10.1155\/2019\/8309103","article-title":"Mesenchymal stem cell conditioned media ameliorate psoriasis vulgaris: a case study","volume":"2019","author":"Seetharaman","year":"2019","journal-title":"Case Rep Dermatol Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s12035-020-01889-3","article-title":"Current and future therapies for psoriasis with a focus on serotonergic drugs","volume":"57","author":"Martins","year":"2020","journal-title":"Mol Neurobiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/13510002.2018.1462027","article-title":"Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells","volume":"23","author":"Lai","year":"2018","journal-title":"Redox Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1021\/acs.jmedchem.0c00055","article-title":"Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as novel, potent, and selective NF-\u03baB Inducing Kinase (NIK) inhibitors for the treatment of psoriasis","volume":"63","author":"Zhu","year":"2020","journal-title":"J Med Chem"},{"key":"B86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jdermsci.2014.02.006","article-title":"The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants","volume":"74","author":"Sugiura","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.712313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T23:37:30Z","timestamp":1645400250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.712313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":96,"alternative-id":["10.3389\/fmed.2022.712313"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.712313","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"article-number":"712313"}}